<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>A study was carried out in 73 male or female patients suffering from mild vascular <z:hpo ids='HP_0000726'>dementia</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>The experimental protocol involved an initial run-in period (14 days) and subsequent double-blind, randomized treatment with 300 mg buflomedil or placebo given orally twice daily for 90 days </plain></SENT>
<SENT sid="2" pm="."><plain>At the end of this treatment period, <z:hpo ids='HP_0000001'>all</z:hpo> patients received buflomedil for a further 90 days and, thereafter, patients received buflomedil or no further treatment for another 90 days </plain></SENT>
<SENT sid="3" pm="."><plain>The efficacy of buflomedil was monitored using rating scales and neuropsychological tests </plain></SENT>
<SENT sid="4" pm="."><plain>The findings of the study indicate that buflomedil improved the symptoms of vascular <z:hpo ids='HP_0000726'>dementia</z:hpo>; the most improvement was recorded in patients who had received buflomedil for the longest period </plain></SENT>
<SENT sid="5" pm="."><plain>Inadequacy, cooperation, psycho-<z:e sem="disease" ids="C0525045" disease_type="Mental or Behavioral Dysfunction" abbrv="">affective disorders</z:e>, self-care and somatic complaints were positively influenced by buflomedil </plain></SENT>
<SENT sid="6" pm="."><plain>The efficacy of buflomedil may be due to its effects on platelet aggregation and improvement in blood flow distribution to the ischaemic brain and oxygenation of brain tissue </plain></SENT>
</text></document>